CuraCell Partners with ScaleReady in cGMP Manufacturing Optimization

April 10th, 2025

CuraCell signes collaboration agreement with ScaleReady under the G-REX Grant Program Initiative aimed to advance state of the art cell and gene-modified cell therapy (CGT) development and manufacturing.

ScaleReady, with support from Wilson Wolf Corporation, Bio-Techne Corporation (NASDAQ: TECH), and CellReady will support CuraCell in process development and manufacturing optimization of CC-38, CuraCell’s Tumor Infiltrating Lymphocytes (TIL) product. ScaleReady’s growing consortium of G-Rex Grant Partners brings best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs and CGT business operations.

“This collaboration helps us advance a TIL-cell therapy that can help patients suffering from solid tumors with dire prognoses. We are honored to be awarded a ScaleReady G-Rex Grant and appreciate the support that ScaleReady and its partners are giving to help us optimize our processes beyond our Phase I/IIa clinical trial.” said Dr. Lucas Arruda, CSO of CuraCell.